https://www.aigom.it/wp-content/uploads/2024/02/JCO29.png863893Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-02-29 13:19:132024-03-01 08:38:53RANDOMIZED PHASE III STUDY COMPARING NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VS CHEMORADIATION IN STAGE IB2-IIB2 CERCIVAL CANCER: EORTC-5594
https://www.aigom.it/wp-content/uploads/2024/02/16-17FEBB-PREV.jpg7931052Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-23 14:46:172024-02-28 08:42:42VENERDÌ 16 – SABATO 17 FEBBRAIO 2024 NEGRAR DI VALPOLICELLA (VR) SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA
https://www.aigom.it/wp-content/uploads/2024/02/ONCOFERTILITa-1.jpg7931052Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-23 09:25:082024-02-23 10:20:258-11 maggio • 3-5 ottobre 2024 | CORSO di ALTA FORMAZIONE in ONCOFERTILITA’2024
https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-15feb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-15 15:00:492024-02-15 15:00:49ATEZOLIZUMAB CON O SENZA RADIOTERAPIA PER IL CARCINOMA SQUAMOSO AVANZATO DEL PENE (STUDIO PERICLES): TRIAL DI FASE II
https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-9febb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-09 13:42:322024-02-09 13:43:30STUDIO KATHERINE: T-DM1 adiuvante vs trastuzumab per EBC HER2+ con malattia residua dopo terapia neoadiuvante (chemioterapia e anti-HER2). Analisi finale della IDFS e seconda interim analisi della OS.
https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-5feb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-05 09:02:192024-02-05 09:02:19PROPHYLACTIC RADIATION THERAPHY VERSUS STANDARD OF CARE FOR PATIENTS WITH HIGH-RISK ASYMPTOMATIC BONE METASTASIS: A MULTICENTER, RANDOMIZED PHASE II CLINICAL TRIAL.
